文献速递白血病淋巴瘤

阿可替尼与伊布替尼治疗慢性淋巴细胞白血病患者的真实世界疗效比较

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

基于Flatiron Health数据库的回顾性真实世界分析,纳入2018年1月1日至2021年2月28日启动阿可替尼或伊布替尼治疗的慢性淋巴细胞白血病患者2509例,比较至治疗终止时间。加权后阿可替尼组12个月终止率22%低于伊布替尼组31%(P=.005),额外校正后阿可替尼终止风险降低41%(HR 0.59)。

要点

  • 阿可替尼组加权后12个月终止率为22%,伊布替尼组为31%(P=.005)。
  • 额外校正后阿可替尼组终止风险较伊布替尼组降低41%(HR 0.59;95%CI 0.43-0.81;P=.001)。
  • 阿可替尼组中位至终止时间未达到,伊布替尼组为23.4个月。

核心结论

  • 在目前规模最大的BTK抑制剂比较研究中,接受阿可替尼治疗的慢性淋巴细胞白血病患者较接受伊布替尼者终止治疗率更低、至终止治疗时间更长。

研究设计与样本

  • 采用Flatiron Health数据库开展的回顾性真实世界分析,纳入2018年1月1日至2021年2月28日启动阿可替尼或伊布替尼治疗的慢性淋巴细胞白血病患者2509例。
  • 分析中89.6%接受伊布替尼,14.1%接受阿可替尼;主要结局为至治疗终止时间(TTD),采用Kaplan-Meier法估计未加权和加权中位TTD,加权Cox比例风险模型比较两组TTD。

主要发现

  • 未加权分析中两组至治疗终止时间无显著差异。
  • 加权后两组除心血管危险因素和基线用药外所有基线特征均衡;阿可替尼组中位至治疗终止时间未达到(95%CI 25.1至未达到),伊布替尼组为23.4个月(95%CI 18.1-28.7)。
  • 加权后12个月终止率阿可替尼组为22%,伊布替尼组为31%(P=.005)。
  • 额外校正既往BTK抑制剂使用后,阿可替尼组终止风险较伊布替尼组降低41%(HR 0.59;95%CI 0.43-0.81;P=.001)。

关键数值与推荐

  • 加权后12个月终止率:阿可替尼组22% vs 伊布替尼组31%(P=.005)。
  • 额外校正既往BTK抑制剂使用后终止风险:阿可替尼组较伊布替尼组降低41%(HR 0.59;95%CI 0.43-0.81;P=.001)。
  • 加权中位至治疗终止时间:阿可替尼组未达到(95%CI 25.1至未达到)vs 伊布替尼组23.4个月(95%CI 18.1-28.7)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel agents, including Bruton tyrosine kinase inhibitors (BTKis), have become the standard of care for patients with chronic lymphocytic leukemia (CLL). We conducted a real-world retrospective analysis of patients with CLL treated with acalabrutinib vs ibrutinib using the Flatiron Health database. Patients with CLL were included if they initiated acalabrutinib or ibrutinib between 1 January 2018 and 28 February 2021. The primary outcome of interest was time to treatment discontinuation (TTD). Kaplan-Meier analysis was used to estimate unweighted and weighted median TTD. A weighted Cox proportional hazards model was used to compare the TTD between cohorts. Of the 2509 patients included in the analysis, 89.6% received ibrutinib, and 14.1% received acalabrutinib. TTD was not significantly different between cohorts in the unweighted analysis. After weighting, the cohorts were balanced on all baseline characteristics except cardiovascular risk factors and baseline medications use. The median (95% confidence interval [CI]) TTD was not reached (NR; 95% CI, 25.1 to NR) for the acalabrutinib cohort and was 23.4 months (95% CI, 18.1-28.7) for the ibrutinib cohort. The discontinuation rate at 12 months was 22% for the weighted acalabrutinib cohort vs 31% for the weighted ibrutinib cohort (P = .005). After additional adjustment for prior BTKi use, the acalabrutinib cohort had a 41% lower risk of discontinuation vs ibrutinib (hazard ratio, 0.59; 95% CI, 0.43-0.81; P = .001). In the largest available study comparing BTKis, patients with CLL receiving acalabrutinib demonstrated lower rates of discontinuation and a prolonged time to discontinuation vs those receiving ibrutinib.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Roeker LE, DerSarkissian M, Ryan K, et al. Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Adv. 2023. PMID: 37163361. doi:10.1182/bloodadvances.2023009739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。